Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Head & Neck 1

Conditions

Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Fibromatosis, Gingival, 2 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Istiratumab × Clear all
NCT02399137 2018-09-18

CARRIE

Merrimack Pharmaceuticals

Phase 2 Completed
88 enrolled
Gastrointestinal

Fibromatosis, Gingival, 2, Pancreatic Neoplasms

NCT02538627 2017-09-05

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

Merrimack Pharmaceuticals

Phase 1 Terminated
5 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms

NCT01733004 2016-08-04

A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

Merrimack Pharmaceuticals

Phase 1 Completed
42 enrolled
Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Hepatocellular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡